Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells by Hammad, Hamida et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
JEM © The Rockefeller University Press  $15.00
Vol. 204, No. 2,  February 19, 2007  357–367  www.jem.org/cgi/doi/10.1084/jem.20061196
357
Asthma is a Th2 lymphocyte-mediated infl  am-
matory disease characterized by airway eosino-
philia and remodeling, goblet cell hyperplasia, 
and bronchial hyperresponsiveness. The pros-
taglandin (PG) series of arachidonic acid me-
tabolites are potent regulators of infl  ammation. 
Mast cell–derived prostaglandin D2 (PGD2) is 
a proinfl  ammatory mediator causing vasodila-
tion, bronchoconstriction, and chemoattrac-
tion of eosinophils and Th2 cells (1, 2). It is 
found in increased levels in the bronchoalveo-
lar lavage (BAL) fl  uid of atopic asthmatics and 
mice with experimentally induced asthma (3, 4). 
Mice overexpressing the lipocalin-type PGD 
synthase in the lungs demonstrated enhanced 
features of asthma (5), whereas reduction of 
PGD2 synthesis by uteroglobin was associated 
with reduced allergic infl  ammation (3).
The paradigm that PGs promote infl  amma-
tion was challenged by experiments showing 
that genetic defi  ciency of the cyclooxygenase 
(COX)-1 and -2 enzymes unexpectedly led to 
strongly enhanced features of asthma through 
defi  cient production of PGD2 and/or prosta-
glandin E2 (PGE2) (6). Similarly, nonsteroidal 
antiinfl   ammatory drugs such as aspirin or 
COX inhibitors that block PG synthesis are 
largely ineff  ective in the treatment of asthma 
and can even exacerbate it (7). The exact role 
of a specifi  c prostanoid in the infl  ammatory 
response is often ambiguous. By acting on 
diff  erent subtype receptors on both hemato-
poietic and nonhematopoietic cells, PGs can 
exert opposing pro- or antiinfl  ammatory ef-
fects (8–10). For example, PGE2 promotes or 
suppresses Th2 responses by acting on the 
E prostanoid (EP)4 receptor or EP3 receptor, 
respectively (11).
Whether PGD2 could also have antiinfl  am-
matory eff  ects through selective usage of the D 
prostanoid (DP)1 or DP2 receptor is currently 
unknown (9). Mice constitutively   defi  cient in 
Activation of the D prostanoid 1 receptor 
suppresses asthma by modulation of lung 
dendritic cell function and induction 
of regulatory T cells
Hamida Hammad,1 Mirjam Kool,1 Thomas Soullié,1 Shuh Narumiya,2 
François Trottein,3 Henk C. Hoogsteden,1 and Bart N. Lambrecht1
1Department of Pulmonary Medicine, Erasmus Medical Center, 3015 GE Rotterdam, Netherlands
2Department of Pharmacology, Faculty of Medicine, Kyoto University, Kyoto 606-8501, Japan
3Institut National de la Santé et de la Recherche Médicale, Unit 547, Institut Pasteur de Lille, Lille 59019, France
Prostaglandins (PGs) can enhance or suppress infl  ammation by acting on different receptors 
expressed by hematopoietic and nonhematopoietic cells. Prostaglandin D2 binds to the 
D prostanoid (DP)1 and DP2 receptor and is seen as a critical mediator of asthma causing 
vasodilation, bronchoconstriction, and infl  ammatory cell infl  ux. Here we show that inhala-
tion of a selective DP1 agonist suppresses the cardinal features of asthma by targeting the 
function of lung dendritic cells (DCs). In mice treated with DP1 agonist or receiving DP1 
agonist-treated DCs, there was an increase in Foxp3+ CD4+ regulatory T cells that sup-
pressed infl  ammation in an interleukin 10–dependent way. These effects of DP1 agonist on 
DCs were mediated by cyclic AMP–dependent protein kinase A. We furthermore show that 
activation of DP1 by an endogenous ligand inhibits airway infl  ammation as chimeric mice 
with selective hematopoietic loss of DP1 had strongly enhanced airway infl  ammation and 
antigen-pulsed DCs lacking DP1 were better at inducing airway T helper 2 responses in the 
lung. Triggering DP1 on DCs is an important mechanism to induce regulatory T cells and to 
control the extent of airway infl  ammation. This pathway could be exploited to design novel 
treatments for asthma.
CORRESPONDENCE
Bart N. Lambrecht:
b.lambrecht@erasmusmc.nl
Abbreviations used: BAL, 
bronchoalveolar lavage; BHR, 
bronchial hyperresponsiveness; 
COX, cyclooxygenase; DP, 
D prostanoid; EP, E prostanoid; 
i.t., intratracheal; mDC, 
  myeloid DC; MHC, metacholine; 
MLN, mediastinal LN; pDC, 
plasmacytoid DC; PenH, 
  enhanced pause; PG, prostaglan-
din; PGD2, prostaglandin D2; 
PGE2, prostaglandin E2; PKA, 
protein kinase A.
The online version of this article contains supplemental material.358  SUPPRESSION OF ASTHMA BY D PROSTANOID 1 RECEPTOR LIGATION | Hammad et al.
the DP1 receptor had severely impaired features of asthma 
(12). The proasthmatic eff  ects of PGD2 could also be medi-
ated by DP2 (also known as CRTH2), mediating direct 
  chemoattraction of eosinophils, basophils, and Th2 cells and 
bronchial hyperreactivity (2, 13–15), although again this 
issue is controversial (16). PGD2 can also recruit infl  amma-
tory cells indirectly by inducing Th2-selective chemokines 
(e.g., monocyte-derived chemokine CCL22) in bronchial 
epithelial cells, although the precise DP receptor involved is 
unknown (17).
Figure 1.  Administration of the DP1 agonist BW245C suppresses 
asthma features. Mice were sensitized by an i.p. injection of OVA-alum 
on days 0 and 7. On days 17–20, mice were exposed to OVA aerosols. 
30 min before each aerosol, mice received an i.t. injection of Vehicle 
(white), PGD2 (grey), BW245C (black), or DK-PGD2 (hatched). (A) BAL fl  uid 
was analyzed by fl  ow cytometry. *, P < 0.05. (B) May Grunwald Giemsa 
staining of lung sections. (C) BW245C inhibits the induction of BHR. 
Airway obstruction to increasing doses of inhaled metacholine for PenH 
responses (% increase from saline) or to i.v metacholine for changes in 
resistance (R) and lung compliance (C) were measured 24 h after the last 
antigen exposure. *, P < 0.05. (D) Cytokine measurements of MLN cells 
restimulated in vitro for 4 d with OVA. *, P < 0.05. (E) BAL supernatants 
were collected and assayed for the presence of IL-5 and IL-13. (F) The 
percentage of Foxp3+ cells in CD4+CD25+ or CD4+CD25− T cells in MLNs 
was determined by fl  ow cytometry. CD4+CD25+ and CD4+CD25− T cells 
were also stained intracellularly for the presence of IL-10. n = 8 
mice/group. Bar, 85 μm. conc., concentration.JEM VOL. 204, February 19, 2007  359
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We now show that treatment with a DP1 agonist po-
tently inhibits the cardinal features of asthma by altering the 
function of lung DCs. These cells are derived from the he-
matopoietic system and play a critical role in asthma patho-
genesis by inducing Th2 sensitization to inhaled allergen and 
by mounting eff  ector Th2 responses in already established 
airway infl  ammation. (18–21). Although our data seem to 
contradict the observed reduction in asthma in constitutive 
DP1−/− mice, we furthermore show that chimeric mice with 
hematopoietic deletion of DP1 had strongly enhanced eosino-
philic airway infl  ammation through enhanced DC function. 
This antiinfl  ammatory DP1 pathway might be exploited for 
the design of new asthma therapeutics.
RESULTS
Treatment with a selective DP1 agonist during OVA 
challenge suppresses asthma
To study the exact contribution of the two DP receptors in 
asthma, we administered PGD2, the selective DP1 agonist 
BW245C, or the selective DP2 agonist DK-PGD2 at the 
time of allergen challenge in OVA-sensitized BALB/c mice. 
Mice receiving vehicle before each OVA aerosol challenge 
developed BAL fl  uid and peribronchial lung tissue eosino-
philia and lymphocytosis, accompanied by Th2 cytokine 
production in the mediastinal LNs (MLNs) (Fig. 1, A and B). 
BW245C treatment strongly suppressed infl  ammation, 
whereas PGD2 or 13,14-dihydro-15-keto–PGD2 was with-
out eff  ect. Bronchial hyperresponsiveness (BHR) to nonspe-
cifi  c stimuli like metacholine is one of the defi  ning symptoms 
of allergic asthma. BHR was fi  rst assessed by measuring the 
enhanced pause (PenH) using whole body plethysmograpy in 
response to inhaled metacholine in awake mice. BHR to in-
haled metacholine was attenuated by BW245C treatment 
(Fig. 1 C). As shown in Fig. 1 C, the allergen challenge of 
OVA-sensitized mice induced a signifi  cant change (P < 0.05) 
in responsiveness to i.v. metacholine compared with sham-
sensitized mice, as measured 24 h after the last OVA aerosol 
challenge by invasive measurement of dynamic resistance (R) 
and compliance (C) in mechanically ventilated mice. Inhala-
tion of BW245C before each allergen challenge markedly 
  attenuated the OVA-induced change in metacholine re-
sponsiveness. Strikingly, in BW245C-treated mice the lev-
els of the immunoregulatory cytokine IL-10 in MLN cells 
were higher, whereas the levels of IL-4, IL-5, and IFN-γ 
were identical compared with vehicle-treated mice (Fig. 
1 D). Strikingly, the levels of Th2 cytokines measured in the 
BAL of BW245C-treated mice were reduced compared with 
mice treated with the vehicle (Fig. 1 E), suggesting a local ef-
fect of BW245C on Th2 cytokine production. Intracellular 
cytokine staining on MLN cells revealed that IL-10 pro-
duction was detectable in CD4+ cells. When gated on 
CD4+CD25+ and CD4+CD25− MLN T cells, both subsets 
contained IL-10 and levels were consistently higher in mice 
treated with BW245C compared with vehicle (Fig. 1 F). 
Within CD4+CD25+ cells, a considerable proportion of cells 
expressed the regulatory T (T reg) cell–associated transcription 
Figure 2.  The antiinfl  ammatory effect of BW245C is dependent 
on DP1 receptor expression on BM-derived cells. WT BM chimeras 
and DP1 knockout mice BM chimeras were sensitized and challenged as 
in Fig. 1. (A) BAL fl  uid differential counts. (B) Airway obstruction to in-
creasing doses of inhaled metacholine was measured as increase in PenH 
values (% increase from saline) 24 h after the last antigen exposure. 
(C) CD4+CD25+ T cells from MLNs of WT or DP1 knockout mice BM 
  chimeras were stained intracellularly for the presence of IL-10. The per-
centage of Foxp3+ cells in CD4+CD25+ T cells was determined by flow 
cytometry. Data are shown as mean ± SEM. *, P < 0.05. n = 8 mice per 
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factor Foxp3, and this percentage was strongly enhanced in 
BW245C-treated mice.
To exclude nonspecifi  c eff  ects of BW245C treatment on 
another prostanoid receptor, we made chimeric mice in 
which the DP1 receptor is absent on hematopoietic cells by 
reconstituting lethally irradiated WT C57BL/6 mice with 
DP1−/− C57BL/6 BM cells or as a control with WT cells. In 
chimeric DP1−/− mice, there was a remarkable fourfold in-
crease in the degree of eosinophilic airway infl  ammation 
compared with WT chimeric mice (Fig. 2 A). Treatment 
with BW245C had the same antiinfl  ammatory eff  ects in the 
WT C57BL/6 strain as in BALB/c mice but did not suppress 
infl  ammation or BHR in DP1−/− chimeric mice (Fig. 2, 
A and B). Intracellular cytokine staining on MLN cells showed 
IL-10 production in CD4+CD25+ cells of WT and DP1−/− 
BM chimeric mice. IL-10 levels were consistently higher in 
cells of WT BM chimeric mice treated with BW245C com-
pared with vehicle (Fig. 2 C). Moreover, the percentage of 
Foxp3+ cells was strongly enhanced in BW245C-treated WT 
chimeric mice. No increased expression of IL-10 and Foxp3 
was observed when DP1−/− chimeric mice were treated with 
BW245C compared with vehicle (Fig. 2 C).
Treatment with DP1 agonist during challenge 
alters DC maturation
As PGD2 and BW245C alter some functions of DCs in vivo 
(22), and ongoing allergic responses depend on DCs (21), we 
next studied the treatment eff   ect on DC maturation. In 
BW245C-treated WT chimeric mice, there was a signifi  -
cantly reduced expression of the maturation marker CD86, 
CD40, and MHC II on lung DCs of OVA-challenged mice 
(Fig. 3 A). Interestingly, these eff  ects of BW245C were abol-
ished in DP1−/− chimeric mice, except for CD40 whose ex-
pression was still reduced compared with vehicle-treated 
mice (Fig. 3 B). Intracellular IL-10 levels were clearly detect-
able in lung-derived DCs from OVA-exposed mice (23), but 
BW245C treatment did not lead to an increased expression 
(Fig. 3 D).
To more directly study the eff  ect on DC maturation, we 
treated BM DCs in vitro with BW245C. Our commercially 
Figure 3.  DP-1 activation affects the phenotype of DCs. Mice 
were sensitized and challenged and treated with DP agonists as in Fig. 1. 
(A) Single cell suspension was prepared from the lungs of WT or DP1−/− BM 
chimeric mice, and CD11c+MHCIIhi lung DCs were analyzed for their expres-
sion of CD40, CD86, and MHC II. Data are shown as mean fl  uorescence 
intensity ± SEM. *, P < 0.05. MFI, mean fl  uorescence intensity (B) BMDCs 
from WT or DP-1 knockout mice were pulsed or not with 100 μg/ml 
of OVA overnight. DCs were also treated for 30 min with vehicle 
(Vehicle/OVA-DCs) or BW245C before addition of OVA (BW245C/OVA-
DCs). DCs were collected, and the expression of CD40, CD80, CD86, and 
MHC II was analyzed by fl  ow cytometry. (C) Analysis of intracellular IL-10 
staining in CD11c+MHCIIhi DCs of OVA-challenged mice treated or not 
with BW245C.JEM VOL. 204, February 19, 2007  361
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available batch of OVA contains trace amounts of LPS suffi   -
cient to induce some degree of DC activation (up-regulation 
of CD40 and CD86) (Fig. 3 C). The treatment of OVA-DCs 
with BW245C strongly suppressed the increase in CD86 and 
MHC II expression, an eff  ect that was not present when DCs 
were derived from DP1−/− donors. Again the suppression of 
CD40 was DP1 independent. In DP1−/− DCs, the levels of 
OVA-induced CD40, CD86, and MHC II were consistently 
high and unimodal, whereas in WT DCs some cells were still 
in an immature CD86low MHC IIlow state.
DP1 ligation inhibits the induction of airway Th2 responses 
by lung myeloid DCs
To prove more directly that DP1 ligation can suppress the 
function of lung DCs in vivo, we used a model in which Th2 
sensitization depends on endogenous lung myeloid (m)DCs 
(20). Mice were fi  rst depleted of tolerogenic plasmacytoid 
(p)DCs by treatment with anti–Gr-1 antibodies, thus leading 
to priming to inhaled harmless OVA. In Gr-1–treated mice, 
but not in control mice, OVA inhalation led to strong airway 
eosinophilia and lymphocytosis (Fig. 4, A and B). Mice 
treated with BW245C at the time of OVA priming no longer 
developed signs of airway infl  ammation. To rule out any 
indirect effects of BW245C on lung structural cells, we 
performed experiments in which BM-derived mDCs were 
treated in vitro with BW245C before adoptive transfer to the 
airways in vivo, a protocol leading to Th2 sensitization and 
features of asthma in BALB/c and C57BL/6 mice (19 and 
Fig. 5, A and B). The pretreatment of OVA-DCs with 
BW245C inhibited their capacity to prime for airway infl  am-
mation and Th2 responses in the MLN in a DP1-dependent 
way (Fig. 5 B). BW245C-pretreated OVA-DCs induced 
higher levels of IL-10 and IFN-γ compared with vehicle. 
Strikingly, OVA-DCs from DP1−/− mice were consistently 
more eff  ective at inducing airway infl  ammation compared 
with WT DCs and also induced the highest levels of IL-5 in 
the LN. Analogous to treatment in vivo (Fig. 1 E), pretreat-
ment of WT OVA-DCs with BW245C led to an increase in 
the percentage of CD4+CD25+Foxp3+ T cells and IL-10+ 
T cells in the MLNs; the latter eff  ects were dependent on 
DP1 (Fig. 5 C).
DCs exposed to DP1 agonist in vitro induce 
the differentiation of T reg cells with 
antiinfl  ammatory potential
The inhibitory eff  ects of BW245C on induction of asthma 
suggested that DP1 ligation profoundly altered T cell po-
larization. To gain more information on this process, we 
next studied DC-driven T cell responses of OVA-specifi  c 
(DO11.10) T cells in vitro. BW245C-treated OVA-DCs in-
duced a lower proliferation and lower production of IL-5 in 
DO11.10 T cells compared with vehicle-treated OVA-DCs 
(Fig. 6, A and B), whereas the levels of the immunoregula-
tory cytokine IL-10 were strongly increased. The levels of 
IFN-γ induced by OVA-DC were unaff  ected by BW245C. 
Moreover, the percentage of CD4+25+Foxp3+ cells was 
  increased when T cells were cocultured with BW245C/
OVA-DCs compared with cells cocultured with vehicle/
OVA-DCs (Fig. 6 C). As we found high levels of IL-10 in-
duction and a higher number of Foxp3+ T cells with 
BW245C-treated OVA-DCs in vitro and in vivo (Fig. 1 D 
and Fig. 5 C) associated with a reduced proliferation of naive 
T cells, and we found increased numbers of Foxp3+CD25+ 
cells in vivo (Fig. 1 F and Fig. 5 C), we investigated 
whether BW245C-treated OVA-DCs induce the diff  erentia-
tion of T reg cells. As shown in Fig. 6 C, when OVA-DC–
stimulated DO11.10 T cells were added to splenocytes and 
fresh naive DO11.10 T cells, OVA-specifi  c T cell prolifera-
tion was stronger because of the presence of eff  ector cells. 
However, BW245C/OVA-DC–stimulated T cells reduced 
the proliferation of fresh naive OVA-specifi  c T cells in re-
sponse to OVA-pulsed splenocytes.
To prove DP1 ligation on DCs could also induce the dif-
ferentiation T cells with regulatory properties in vivo, CD4+ 
T cells obtained from the MLNs of mice injected with OVA-
DCs or with BW245C/OVA-DCs were transferred into 
OVA-alum–sensitized recipients. When CD4+ T cells from 
OVA-DC–injected mice were transferred, the number of 
eosinophils in the BAL fl   uid was substantially increased 
compared with mice that did not receive T cells (Fig. 6 E). 
Figure 4.  Administration of BW245C affects lung myeloid DCs 
and inhibits airway infl  ammation. On day 0, mice received an i.t. injection 
of OVA in the presence or in the absence of BW245C. From days −1 to 2, 
mice were injected i.p. with anti–Gr-1 antibodies to deplete pDCs or 
  isotype control antibodies. 10 d later, mice were exposed to three OVA 
aerosols. (A) BAL fl  uid was analyzed by fl  ow cytometry. Data are shown 
as mean ± SEM. (B) May Grunwald Giemsa staining of lung sections. 
Bar, 85 μm .362  SUPPRESSION OF ASTHMA BY D PROSTANOID 1 RECEPTOR LIGATION | Hammad et al.
The adoptive transfer of CD4+ T cells obtained from mice 
injected with BW245C/OVA-DCs could, however, partially 
inhibit BAL eosinophilia, suggesting the presence of T reg 
cell activity.
Some T reg cells suppress infl  ammation through the anti-
infl  ammatory cytokine IL-10. To address if enhanced IL-10 
secretion (Fig. 5 B) was responsible for the absence of 
asthmatic infl  ammation in BW245C/OVA-DC–immunized 
mice, some mice received an i.p injection of blocking anti–
IL-10R antibodies 1 d before the OVA aerosol exposure 
  period. The injection of anti–IL-10R antibodies to BW245C/
OVA-DC–immunized mice restored airway eosinophilia 
(Fig. 6 F) to levels observed in OVA-DC–immunized mice. 
To directly prove that recipient IL-10 was necessary for 
the observed inhibitory eff   ect, the next approach was to 
transfer BW245C-treated or untreated OVA-DCs into either 
WT or IL-10−/− C57BL/6 recipients. BW245C/OVA-DCs 
failed to induce airway eosinophilia and lymphocytosis 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20061196) and IL-5 cytokine production in MLN in WT 
recipient mice, but on the contrary strongly boosted airway 
infl  ammation when injected into IL-10−/− recipient mice 
(not depicted). The production of IL-5 by MLN T cells of 
IL-10−/− recipients was considerably increased compared with 
WT recipient mice but only when OVA-DCs were pretreated 
with BW245C (unpublished data).
DP1 ligation of DCs alters DC function through 
cAMP-dependent protein kinase A activation
The seven transmembrane-spanning G protein–coupled DP1 
receptor is known to stimulate adenyl cyclase through Gαs 
proteins. In infl  ammatory and immune cells an accumulation 
of cAMP is generally associated with suppression of eff  ector 
functions, partially through activation of the cAMP-dependent 
protein kinase A (PKA) pathway. As shown in Fig. 6 G, 
BW245C pretreatment of OVA-pulsed DCs was no longer 
able to induce the production of IL-10 in naive DO11.10 
T cells in the presence of a PKA antagonist Rp-8-Br-cAMP 
(5 μM), whereas exposure of OVA-pulsed DCs to a stable 
cell-permeable cAMP analogue 8-Br-cAMP (1 μM) mim-
icked the eff  ects of BW245C in inducing high levels of IL-10 
production in T cells. Similarly, the eff  ects of BW245C in 
inhibiting DC maturation (CD40 up-regulation) of BM-
  derived DCs were abolished in the presence of a PKA inhibi-
tor and mimicked by stable cAMP analogues (Fig. 6 H; 
similar data not shown for CD80, CD86, and MHCII).
Figure 5.  BW245C treatment of DCs inhibits BAL eosinophilia. 
On day 0, mice received an i.t. injection of vehicle/OVA-DCs, BW245C/
OVA-DCs, or vehicle DCs obtained from WT or DP1 knockout mice. From days 
10–13, mice were exposed to OVA aerosols. (A) BAL fl  uid differential count. 
(B) MLN cells restimulated in vitro for 4 d with OVA and cytokine levels 
measured in the supernatant. (C) Foxp3 and IL-10 expression in CD4+CD25+ 
cells obtained from the MLNs of the animals. Data are shown as 
mean ± SEM. *, P < 0.05. n = 8 mice per group.JEM VOL. 204, February 19, 2007  363
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DISCUSSION
In this paper, we have shown that endogenous PGD2 acting 
at DP1 on BM-derived cells has an important feedback func-
tion in allergic infl  ammation and that administration of a se-
lective DP1 agonist substantially suppresses the elicitation of 
infl  ammatory allergic reactions and bronchial hyperreactiv-
ity. Lung administration of DP1 agonist was able to suppress 
asthma equally well when given during Th2 priming 
in naive mice as during allergen challenge in already sensi-
tized mice, suggesting that selective DP1 agonists might be 
used as a novel class of antiinfl  ammatory drugs.
OVA-sensitized and challenged chimeric DP1−/− mice 
had strongly enhanced airway infl  ammation compared with 
chimeric WT mice. At fi  rst sight, our fi  ndings are in sharp 
contrast to data in constitutive DP1−/− mice that demon-
strated less severe features of asthma (12). In our experiments, 
DP1 defi  ciency was restricted to BM-derived cells, possibly 
explaining the observed diff  erences. It is known that struc-
tural cells of the airway wall such as epithelial cells, fi  bro-
blasts, and smooth muscle cells express the DP1 receptor 
(3, 12) and react to PGD2 by producing Th2-selective chemo-
kines such as CCL22, also known as MDC (17). In constitu-
tive DP1−/− mice, the loss of this epithelial allergy-promoting 
mechanism is possibly dominant over the allergy-promoting 
eff  ect of DP1 defi  ciency on hematopoietic cells, and conse-
quently asthma severity would be reduced. Our data on 
  enhanced Th2 responses in the absence of DP1 are also 
  supported by studies in parasite infection. Schistosoma infec-
tion of the skin led to enhanced Th2 responses and lower 
levels of IFN-γ and IL-10 in DP-1−/− mice compared with 
WT mice (24).
It was previously shown that lipocalin-type PGD synthase 
transgenic mice had strongly enhanced airway infl  ammation, 
again contrary to our fi  ndings (5). The supraphysiological 
amount of PGD2 produced in these transgenics could lead 
to high levels of downstream metabolites 9α-11β-PGF2, 
12-PGD2, 15-deoxy-12,14-PGD2, and DK-PGD2 that more 
selectively act on the chemotactic and proinfl  ammatory DP2 
receptor (CRTH2) on infl  ammatory cells (9) or could act by 
enhancing the epithelial release CCL22, attacking Th2 cells 
(17). It could also mean that in an integrated setting the pro-
infl  ammatory eff  ects of DP2 triggering override any protec-
tive eff  ect of DP1 activation. In our model, we did not fi  nd 
enhancement of airway eosinophilia when PGD2 or the DP2 
agonist DK-PGD2 was administered to the airways, in con-
trast to other reported work (14, 15, 17). The observed dif-
ferences could be caused by subtle variations in the sensitization 
(use of alum adjuvant) and challenge protocol (number of 
OVA aerosols) used for inducing asthma.
When given by inhalation, a selective DP1 agonist sup-
pressed all the cardinal features of asthma, including bronchial 
hyperreactivity. This suggests strongly that any proinfl  amma-
tory eff  ects on structural cells (epithelial cells, fi  broblasts, and 
smooth muscle cells) (3) mediated by DP1 were not strong 
enough to overcome the protective eff  ects of DP1 on hema-
topoietic cells. It is possible that the dose of agonist or its 
  affi   nity for DP1 compared with PGD2 reveals mainly the 
antiinflammatory effects of DP-1 ligation. Alternatively, 
BW245C was crossreacting with some other antiinfl  amma-
tory receptor such as EP3 (11). Crossreactivity was, however, 
excluded by the fi  nding that BW245C lost its antiinfl  amma-
tory activity in DP1−/− mice. Only one eff  ect of BW245C 
(reduction of CD40 expression on DCs) appeared to be 
DP1 independent.
Our fi  ndings in chimeric mice demonstrate that DP1 li-
gation on a BM-derived cell is important for the antiinfl  am-
matory eff   ects of BW245C. The DP1, but not the DP2 
(CRTH2) receptor, is expressed on mouse and human DCs 
(24, 25) and ligation of DP1 alters the migration of lung DCs 
(22). In view of the essential role of DCs in orchestrating 
lung immunity, we hypothesized that DP-1 agonism might 
be antiinfl  ammatory by altering DC function (22). Support-
ing our hypothesis, in BW245C-treated animals or cells ex-
posed in vitro to BW245C, DCs expressed less CD86, CD40, 
and MHCII, known to be essential for inducing naive and 
memory eff  ector responses in the lungs (21, 26). We studied 
the dependency of this inhibition on DP1 and found that the 
eff  ects of BW245C on CD86 and MHC II were DP1 depen-
dent, whereas those on CD40 expression were DP1 indepen-
dent both in vivo and in vitro. We have no explanation for 
these fi  ndings at present, but this suggests that some eff  ects of 
BW245C on DCs could be through another receptor or 
through a metabolite using another receptor.
Further supporting an eff  ect of DP1 ligation on DC func-
tion in the lung, we demonstrated that BW245C suppressed 
priming of Th2 responses via the airways in a model in which 
antigen presentation was restricted to endogenous mDCs (20). 
This was most likely a direct eff  ect of the compound on DCs 
and not an indirect eff  ect on epithelial cells as it could be 
mimicked by ex vivo BW245C treatment of BMDCs before 
adoptive transfer to the airways. Such adoptive transfer leads 
to stable Th2 priming and to asthmatic features in the lungs 
of recipients (19).
Reducing the migration and/or maturation of DCs is one 
likely explanation by which asthma features were suppressed, 
as the induction and maintenance of allergic lung infl  amma-
tion depends on adequate function of mature lung DCs (18, 21). 
In all our in vivo (Fig. 1 D and Fig. 5 B) and in vitro 
(Fig. 6 B) experiments in which DCs were exposed to the 
DP1 agonist BW245C, we noticed a reduction or main-
tenance of Th2 cytokines in the induced T cell response, 
whereas the immunoregulatory cytokine IL-10 was increased. 
The most likely source of this enhanced IL- 10 was CD4+ T 
cells (Fig. 1 F) as we could not detect any increase in intracel-
lular IL-10 in BW245C-exposed DCs (Fig. 3 D). The low 
level proliferation and high level production of IL-10 in 
OVA-specifi  c T cells stimulated by BW245C-treated OVA-
DCs in vitro is reminiscent of adaptive T reg cells. Further-
more, OVA-specifi  c  CD4+ T cells put in culture with 
BW245C-treated DCs strongly up-regulated Foxp3, a tran-
scription factor found at high levels in natural and subsets of 
adaptive T reg cells. These Foxp3+ CD4+CD25+ T reg cells, 364  SUPPRESSION OF ASTHMA BY D PROSTANOID 1 RECEPTOR LIGATION | Hammad et al.
Figure 6.  BW245C treatment of DCs induces T reg cells. Vehicle/
OVA-DCs, BW245C/OVA-DCs, and unpulsed DCs (Vehicle DCs) were co-
cultured for 4 d with naive OVA-specifi  c CD4+ T cells. (A) Cell proliferation 
after a 16-h pulse. (B) Cytokines in the supernatant. (C) Foxp3 expression. 
(D) Regulatory T cell assay in vitro. Proliferation of OVA-specifi  c T cells 
after a 2-d co-culture with syngeneic splenocytes and OVA peptide in the 
presence of T cells previously stimulated with vehicle/OVA-DCs (T-Vehicle/
OVA-DCs) or BW245C/OVA-DCs (T-BW-DCs). (E) Regulatory T cell assay 
in vivo. On day 0, mice received an i.t. injection of vehicle/OVA-DCs, 
BW245C/OVA-DCs, or unpulsed DCs (Vehicle DCs). From days 10–13, mice JEM VOL. 204, February 19, 2007  365
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known to suppress infl  ammation via IL-10 in vivo, were also 
increased in vivo after BW245C treatment (Fig. 1 F) and in 
mice receiving BW245C-treated DCs (Fig. 5) in a DP1-
  dependent manner. We do not know at present whether the 
increase in Foxp3+ CD4+CD25+ cells is the result of expan-
sion or recruitment of naturally occurring T reg cells or 
whether they are induced de novo from naive antigen-
  specifi  c T cells in the periphery (27).
The main discriminating feature of induced and natural T 
reg cells is their capacity to reduce T cell proliferation upon 
co-culture with naive T cells or infl  ammation in vivo. Sev-
eral data in our paper suggest that functional T reg cells were 
indeed induced. First, OVA-specifi  c T cells that were ini-
tially stimulated by DP1-treated OVA-DCs partially inhib-
ited the proliferation of fresh OVA-specifi  c T cells. Second, 
T cells obtained from BW245C/OVA-DC–immunized mice 
and transferred to OVA-alum–sensitized mice partially inhib-
ited OVA aerosol-induced eosinophilic airway infl  ammation 
in vivo, a classic example of T reg cell activity (23, 28, 29). 
Third, and most importantly, the immunomodulatory eff  ect 
of BW245C on DCs in vivo was dependent on bioactive IL-10 
from the host, as shown by IL-10R blocking experiments or 
transfer into IL-10–defi  cient recipients in vivo. By analogy, 
Kearley recently demonstrated that OVA-specifi  c CD4+CD25+ 
T reg cells suppressed airway infl  ammation through induc-
tion of host IL-10 production (29). In IL-10–defi  cient mice, 
BW245C-treated DCs even induced stronger Th2 immunity 
and airway infl  ammation, best explained by the previous ob-
servation that PGD2 treatment of splenic DCs in vitro sup-
presses IL-12p70 (30). It seems therefore that DP1 ligation of 
DCs endows these cells with a potential to induce both Th2 
and T reg cell responses, but in vivo the production of IL-
10 is able to suppress the eff  ector functions of Th2 cells.
Exactly how T reg cells are induced by DP1 ligation of 
DCs is likely a complex phenomenon but could be related to 
the capacity of DP1 agonists to raise the levels of intracellular 
cAMP in DCs (30). Several compounds that alter DC func-
tion (such as histamine, β-adenergic agonists, or adenosine) 
do so by raising intracellular cAMP, and this might explain 
some of the antiinfl  ammatory eff  ects described with these 
compounds (31, 32). In support for this pathway, the IL-10–
enhancing eff  ects of BW245C-treated DCs on T cells were 
abolished when the downstream cAMP-dependent PKA was 
blocked using the inhibitor Rp8-Br-cAMP. Conversely, DCs 
treated with the cell-permeable cAMP analogue 8-bromium-
cAMP also induced IL-10 production in responding T cells. 
Additionally, our preliminary experiments show a rise in nu-
clear-associated CREB- 1, a transcription factor binding to 
the consensus cAMP response element in nuclear extracts of 
BW245C-treated DCs. BW245C and 8-Br-cAMP (Fig. 6 
H) treatment inhibits the LPS-driven maturation of DCs 
in vitro, and this process required PKA. Others have shown 
that immature DCs can induce a state of peripheral tolerance 
by induction of T reg cells (23, 27, 33, 34).
Our fi  ndings in DP1−/− chimeric mice, OVA-DP1−/− 
DC-immunized mice, and in vitro DP1−/− BM cultures sug-
gest an endogenous source of PGD2 that tonically inhibits air-
way infl  ammation by suppressing the maturation of DCs. In 
vivo, a predominant source of PGD2 is from IgE-triggered 
mast cells that is mainly known to cause edema and cellular 
  recruitment by directly acting on endothelial and infl  ammatory 
cells. It is tempting to speculate that PGD2 down-regulates DC 
activation in an attempt to keep infl  ammation in check. Other 
predominant sources of PGD2 are macrophages and DCs (35). 
Alveolar macrophages suppress the function of lung DCs by 
maintaining them in an immature state through secretion of 
PGs, but it has not been studied exactly which COX-dependent 
prostanoid (PGD2 or PGE2) is involved (36, 37). The avail-
ability of PGD2 synthase-defi  cient mice and use of reconstitu-
tion experiments in mast cell or macrophage-defi  cient mice 
will in the future solve these outstanding questions.
Finding novel ways to treat allergic infl  ammation is the 
goal of many laboratories in the world. Selective DP1 anta-
gonists have been proposed as novel antiasthmatic drugs with 
the idea of inhibiting the proinfl  ammatory eff  ects of PGD2. 
Our data caution against this strategy as eventually these drugs 
might potentiate allergic sensitization and infl  ammation. We 
favor the idea of fi  nding selective DP1 agonists that exploit 
the full antiinfl  ammatory eff  ect on airway DCs.
MATERIALS AND METHODS
Mice. IL-10−/−, C57BL/6, and BALB/c mice were from The Jackson Lab-
oratory. DP1−/− mice (C57BL/6) were previously described (12). DO11.10 
TCR transgenic mice were bred in house. To prepare BM chimeras, 
C57BL/6 mice were irradiated. All experiments were performed according 
to institutional ethical guidelines.
Preparation of BM chimeric mice. C57BL/6 mice were γ-irradiated 
twice with 5 Gy and were reconstituted with 2 × 106 BM cells from DP1-
defi  cient or WT control mice (CD45.2). At 6–7 wk after reconstitution, 
chimeric mice were used for experiments.
OVA-alum model of asthma. Mice were sensitized to OVA (Worthing-
ton Biochemical) via the i.p. injection of OVA-alum on days 0 and 7, and 
were exposed to OVA aerosols. On day 14, CD4+ T cells were purifi  ed from 
MLNs and injected into recipient mice sensitized with OVA-alum 7 and 
14 d earlier. 3 d after the CD4+ T cell transfer, mice were exposed to three 
OVA aerosols. BAL fl  uid was analyzed by fl  ow cytometry. (F) The inhibitory 
effect of BW245C treatment of DCs is dependent on IL-10. On day 0, mice 
were injected i.t. with unpulsed DCs (Vehicle DCs), vehicle/OVA-DCs, or 
BW245C/OVA-DCs. Some mice were also injected i.p. with blocking anti–
IL-10R antibodies 1 d before aerosol exposure. BAL fl  uid was analyzed by 
fl  ow cytometry. Data are mean value ± SEM. *, P < 0.05. (G) Effects of 
BW245C on DCs depend on cAMP-dependent PKA. DCs were pulsed with 
OVA in the presence of vehicle, the PKA inhibitor Rp8-Br-cAMP, or the 
cell-permeable cAMP analogue 8-Br-cAMP, subsequently washed and put 
into culture with naive DO11.10 T cells. IL-10 production was measured 
4 d later in supernatants. (H) Effects of BW245C in suppressing DC matu-
ration (as indicated by CD40 up-regulation) depend on PKA and are mim-
icked by 8-Br-cAMP.366  SUPPRESSION OF ASTHMA BY D PROSTANOID 1 RECEPTOR LIGATION | Hammad et al.
were challenged with OVA aerosols on days 17–19, delivered from a jet 
nebulizer delivering 1% OVA in PBS for 30 min. 30 min before each OVA 
exposure, mice were anesthetized using avertin and received an intratracheal 
(i.t.) injection of vehicle, or of 100 μM of PGD2, DK-PGD2, or BW245C 
(Cayman Biocemical Corp.). 24 h after the last OVA exposure, BAL was 
performed and cells were stained with anti-CCR3 PE (R & D Systems), 
anti–I-Ad/I-Ed FITC, anti-CD3, and anti-B220 cy-chrome and anti-
CD11c APC (all from BD Biosciences) and analyzed by fl  ow cytometry (38). 
In brief, eosinophils were characterized as CCR3+ SSChi cells, neutrophils 
as CCR3− SSChi cells, lymphocytes as CD19+/CD3+ FSClo cells, and 
macrophages as large autofl  uorescent cells. After BAL was performed, lungs 
were resected, fi  xed, and embedded, and 5-μm sections were performed and 
stained with May Grunwald Giemsa.
In some experiments, lungs were collected and digested with collagen-
ase III and DNase I (39). Single cell suspensions were stained with FITC 
anti–I-Ad/I-Ed, PE-labeled anti-CD40, anti-CD80, anti-CD86, and APC-
labeled anti-CD11c antibodies (all from BD Biosciences).
To measure cytokine levels, MLN cells were plated in round bottom 
96-well plates (106 cells/ml) and restimulated with OVA (10 μg/ml) for 4 d. 
Production of IL-5, IL-10, and IFN-γ was assayed on supernatants by ELISA 
(BD Biosciences).
For intracellular cytokine staining, MLN cells were restimulated in vitro 
for 5 h with PMA, ionomycin, and brefeldin A (all from Sigma-Aldrich). 
Cells were washed and stained with FITC-labeled CD25 and APC-labeled 
anti-CD4 (BD Biosciences). After washing, cells were permeabilized for 20 
min and stained with PE-labeled anti–IL-10 antibodies (BD Biosciences). 
For demonstrating T reg cells, cells were stained with PE-labeled anti-Foxp3 
antibodies (eBioscience).
Th2 sensitization induced by endogenous mDCs. Mice were depleted 
of pDCs by three i.p. injections of anti–Gr-1 antibody (250 μg/mouse) as 
described (20). On day 0, 800 μg of OVA was injected i.t., admixed with 
100 μM of BW245C or vehicle. After a wash out period of 10 d, mice re-
ceived three OVA aerosols of 30 min on three consecutive days, and mice 
were killed 24 h later.
Th2 sensitization induced by i.t. injection of BM-derived mDCs. Bone 
marrow cells were grown in medium containing recombinant murine GM-
CSF (200 IU/ml) (19). At day 9 of culture, cells were pulsed overnight with 
100 μg/ml OVA in the presence of 10 μM BW245C or DMSO vehicle. 
Nonadherent DCs were collected, washed to remove free OVA or BW245C, 
and resuspended in PBS at a concentration of 12.5 × 106 cells/ml. For in 
vivo experiments, BALB/c mice were anesthetized on day 0 with avertin 
(2% vol/vol in PBS), and 106 vehicle DCs, vehicle/OVA-DCs, or BW245C/
OVA-DCs were instilled through the opening vocal cords as described (19). 
On days 10–12, mice were exposed to a 30-min OVA aerosol and killed 
24 h later.
In some experiments, vehicle/OVA-DC and BW245C/OVA-DC–im-
munized mice were injected i.p with 500 μg of blocking anti–IL-10R anti-
bodies (aIL-10R) (BD Biosciences) 1 d before aerosol challenge. Alternatively, 
BMDCs were derived from WT C57BL/6 mice, treated or not with 
BW245C, and injected i.t. into WT or IL-10−/− recipient mice.
Determination of BHR. 24 h after the last OVA aerosol challenge, non-
specifi  c airway responsiveness was measured by exposing awake mice to 
aerosolized PBS to set a baseline value, followed by increasing concentra-
tions of aerosolized metacholine (MCH) using ultrasonic nebulizers. PenH 
values were measured 3 min after each metacholine aerosol using a whole 
body plethysmograph (Buxco, Electronics). The average PenH values were 
expressed for each MCH concentration as the percentage increase over base-
line PenH values.
For invasive measurement of dynamic resistance and compliance, mice 
were anesthetized with urethane, paralyzed using d-tubocurarine, tracheot-
omized, and intubated with an 18-G catheter, followed by mechanical ven-
tilation with a Flexivent apparatus (SCIREQ). Respiratory frequency was set 
at 120 breaths/min with a tidal volume of 0.2 ml, and a positive-end expira-
tory pressure of 2 ml H2O was applied. Increasing concentrations of meta-
choline (0–600 μg/kg−1) were administered via the jugular vein. Dynamic 
resistance and compliance were recorded after a standardized inhalation ma-
neuver given every 10 s for 2 min. Baseline resistance was restored before 
administering the subsequent doses of MCH.
Naive T cell activation and diff  erentiation in vitro. 2 × 105 OVA-
  specifi  c TCR transgenic CD4+ T cells obtained from DO11.10 mice were cul-
tured in vitro in round bottom 96-well plates for 4 d with increasing numbers 
of BALB/c OVA-DCs pretreated with vehicle or with BW245C. In some 
experiments, DCs were also pretreated with the cAMP analogue 8-Br-cAMP 
or with the PKA inhibitor Rp8-Br-cAMP. Cell proliferation of naive T cells 
was assessed by 3H-thymidine (1 μCi/well) uptake in a 16-h pulse. To assess 
Th cell diff  erentiation, supernatants were harvested and analyzed by ELISA.
Induction of regulatory T cells. DCs pulsed with OVA, treated with vehi-
cle or with BW245C, were cultured with naive DO11.10 CD4+ T cells for 
3 d at a 1:10 ratio (20). T cells were harvested and cultured at 5 × 105 cells per 
well without OVA in the presence of 1 ng/ml mouse IL-2 (R & D Systems) 
for an additional 7 d. Regulatory activity was assayed by culturing freshly puri-
fi  ed DO11.10 CD4+ T cells (105 per well) with irradiated BALB/c splenocytes 
(105 per well) in 96-well plates, with 10 μg/ml OVA323-339 peptide, in the 
presence or absence of DC-stimulated T cells (105 per well). Cell proliferation 
was assessed after 48 h by 3H-thymidine (1 μCi/well) uptake in a 16-h pulse.
To address induction of T reg cells in vivo, mice received BW245C-
treated DCs or OVA-pulsed DCs and were challenged with OVA aerosol 
from days 10–12. On day 13, MLNs were collected and CD4+ T cells were 
purifi  ed (purity >95% using magnetic bead purifi  cation; Miltenyi Biotec). 
2 × 106 CD4+ cells were injected i.v. into mice that were sensitized twice 
by injection of OVA-alum. 3 d after injection of CD4+ T cells mice were 
exposed to three OVA aerosols.
Statistical analysis. For all experiments, the diff  erence between was calcu-
lated using the Mann Whitney U test for unpaired data. Diff  erences were 
considered signifi  cant if P < 0.05. Groups consisted of at least eight mice per 
group. Experiments shown are representative of three experiments.
Online supplemental material. Fig. S1 shows numbers of cells in the 
BAL fl  uid of WT or IL-10−/− mice injected i.t. with vehicle/OVA-DCs, 
BW245C/OVA-DCs, or unpulsed DCs. Fig. S1 is available at http://www
.jem.org/cgi/content/full/jem.20061196.
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